Many cancers adapt to chemotherapeutic agents by upregulating membrane efflux pumps that export drugs from the cytoplasm, but this response comes at an energetic cost.
Introduction
Disseminated breast cancer remains almost uniformly fatal largely due to evolution of resistance to available systemic therapies. While some breast cancer patients do not receive any benefit from systemic therapy, most have a good initial response but later develop resistance and the tumor recurs. Typically, response to subsequent therapies is less and less durable until finally no therapy is effective. While de novo resistance may be environment-mediated (due to ischemia, hypoxia or tumor-stroma interactions through adhesion or soluble factors), relapse with tumor progression is generally due to the selection for specific phenotypes that confer chemoresistance (1) .
A common and well-studied mechanism of acquired resistance is increased expression of p-glycoprotein (PGP) membrane pumps, which export a number of different chemotherapeutics from the cytoplasm. Patients treated with doxorubicin and vincristine, both PGP substrates, have shown a direct correlation of PGP detection with Several clinical trials have examined simultaneous administration of chemotherapy and PGP substrates (9) -the latter acting as a competing ligand to increase the intracellular concentration of the former. However, results have been disappointing, in part due to dose limitation of PGP modulators (10, 11) , which typically require micromolar concentrations, which are not clinically attainable.
Recently, our group has suggested that the proliferation of chemoresistant clones could be delayed, if the minimum drug intensity necessary to maintain a stable tumor burden were used, instead of the standard maximum tolerated dose (MTD). This approach was termed "adaptive therapy" (AT) (12) . The basic hypothesis of AT is that, while evolution of resistant strategies is inevitable, proliferation of resistant populations is not. AT seeks to suppress proliferation of resistant cells by exploiting the cost linked to the drug resistance mechanism. That is, chemoresistant cells must synthesize and activate proteins that protect them from chemotherapy. This requires diversion of resources that would otherwise be available for proliferation. Thus, in the absence of chemotherapy, we propose that the chemoresistant cells are significantly less fit than chemosensitive cells.
To exploit this difference, AT applies chemotherapy judiciously to explicitly maintain a small residual population of chemosensitive cells. These cells, during chemotherapy intervals, will proliferate at the expense of the chemoresistant cells. In effect, AT seeks to maintain a population of cells that can be controlled using them to suppress proliferation of cells that cannot be controlled by therapy.
Unlike traditional chemotherapy, which fixes drug dose and schedule, AT aims to fix the size of the tumor, and continuously adjusts the chemotherapy to achieve that goal (12) . Using animal models and computational simulations, our group determined that two 6 factors were decisive for the success of AT: the initial prevalence of chemoresistant cells, and the difference in the growth rate of the two sub-populations during chemotherapy intervals.
While the initial ratios of chemoresistant and chemosensitive cells are inherent to each patient, we hypothesized that the energetic cost of PGP pumps could be manipulated as a means of further reducing the fitness of chemoresistant cells during chemotherapy intervals. This would effectively increase the fitness advantage of the drug sensitive cells and allow them to further out-compete the chemoresistant clones, and further delay tumor progression.
This hypothesis is supported by prior studies demonstrating that PGP+ mutants have accelerated glucose metabolism (13) , and faster ATP depletion in glucose-free medium (14) . Furthermore, increased glucose utilization has been observed in PGP-overexpressing cells when exposed to verapamil or other PGP substrates (15) . Taken together, these observations indicate that PGP+ cells grow in vitro at approximately the same rate as their PGP-counterparts, only because of the abundance of nutrients and oxygen. In hypoxia and low glucose, however, the basal activity of the PGP pumps taxes their growth, an effect exacerbated by the use of PGP-substrates at sub-toxic levels.
In this work, we combined in vitro and computational models to investigate the possibility of maintaining a stable tumor burden by enhancing the energetic cost of therapy resistance. 
Materials and Methods

Cell lines
In this study we used the breast cancer cell lines MCF-7 and the PGP overexpressing chemoresistant MCF-7/Dox. The dose responses of these two cell lines were assessed for doxorubicin, and the IC50 values were determined to be 10.7ng/ml and 476.5ng/ml, respectively. Both cell lines were obtained from American Type Culture Collection or Michigan Cancer Foundation (16) . MCF-7/Dox cells were maintained in the presence of 0.1-0.5 ȝg/ml doxorubicin until one week prior to experiments to ensure maintenance of the resistant phenotype.
Growth rates
The growth rates were determined using two methods: First, we measured the biomass increase by crystal violet staining (17) . Second, we quantified the number of adherent live cells in real time (figure 1) in the xCelligence system (Roche) during 96h, for both cell lines, in normal culture conditions and in reduced glucose (2g/L and 0.5g/L glucose, respectively).
To assess the fitness cost of PGP-mediated chemoresistance, we mixed and plated MCF-7 and MCF-7/Dox cells at a 2:1 ratio. Cells were initially cultured in normal media for 24h, when media was changed, and cells were allowed to grow for additional 72h in 
Metabolism
Previous works (14, 15, 18) suggested that PGP mutants had increased glycolytic metabolism and sensitivity to energy restriction. We studied how the MCF-7 and MCF-7/Dox cell lines differed in terms of glucose consumption, and their main energetic pathway: either anaerobic or aerobic glycolysis.
The glucose uptake rate was estimated by the accumulation of the fluorescent glucose analog 2-NBDG, which is transported by facilitated transport into the cytoplasm and loses fluorescence upon phosphorylation by hexokinase ( figure 3) (19) . The fluorescence in both MCF-7 and MCF-7/Dox cells was measured for 60 minutes, and the ratio between the derivatives of the curves at time 0 minutes was used to determine the fold increase in the glucose transport potential of both cell lines.
We studied the glycolytic metabolism of both cell lines using the XF Analyzer 
Computational model of clinical treatment
The clinical treatment computational model used in this article is an extension of our previous work on AT (12) : the tumor burden of a patient was composed by two sub- Verapamil levels in these simulations (100nM) were chosen due to dose-limiting heart damage, previously observed in clinical trials (10) .
Results
PGP mutants have accelerated glycolytic metabolism
The MCF-7/Dox cells replicate faster than MCF-7 in optimum conditions: 22.4h
vs. 24h. However, the energetic cost of resistance of the basal activity of the PGP pumps becomes a significant burden for these cells under energy restricted conditions: while MCF-7 cells are able to maintain their growth rate in absence of glucose for over 120h, the MCF-7/Dox lose viability after 72h in absence of glucose (figure 1).
Energy restriction and PGP substrates synergistically reverse fitness of PGP mutants
We investigated if the addition of a glycolytic anti-metabolite, and low doses of non-chemotherapeutic PGP substrates, could be used in combination with adaptive therapy to further reduce the fitness of chemoresistant cells during therapy intervals. When co-cultured in optimum glucose conditions, the PGP+ mutant overgrows the parental cell line, but in low glucose concentrations, and in combination with verapamil, the parental cell line out-competes the drug resistant cells (figure 2). verapamil has no effect (note in the column "Low Glucose" the reduction in the number of MCF-7 cells, in gray, when compared to "High Glucose", but no additional difference is observed in the final number of MCF-7 when Verapamil is added to the low glucose media). Similarly, MCF-7/Dox responded to glucose restriction with an increase in the doubling time from 22.4h to 26.3h, while the verapamil alone in high glucose media had no effect. The combination of verapamil and 2-deoxyglucose, however, caused a two-fold increase in doubling time for the PGP mutant (22.4h to 51h). When the chemotherapeutic agent doxorubicin is added to the high glucose media, the PGP mutant became fitter (more surviving cells than the wild type). This dominance was reversed by addition of verapamil or by energy restriction alone.
PGP mutants show up-regulation of glucose uptake
We studied the rate of glucose uptake in both cell lines through accumulation of the fluorescent glucose analog 2-NBDG (figure 3). The initial rate of uptake of the glucose analog in the PGP+ mutant (estimated as the first derivative at time 0') was four times higher than for the parental cell line (165 RFU/min versus 40 RFU/min), indicating that part of the accelerated glucose metabolism observed in the MCF-7/Dox cells is due to an increase in the glucose transporter activity. 
PGP mutants are more dependent on anaerobic glycolysis
In order to estimate the actual ATP production, we made the following assumptions: (1) all oxygen consumed is used in the Krebs cycle, and every six molecules of O 2 consumed produces 36 molecules of ATP; (2) the proton production corresponds to ~85% of the lactate production in atmospheric conditions (pO 2~2 1%) (22); and (3) that every molecule of lactate produced corresponds to the generation of one ATP molecule through anaerobic glycolysis;
Using these assumptions, we generated the chart of figure 3, which suggests three main conclusions: (1) glucose restriction does not significantly affect energy production in MCF-7 cells, but causes a 20% decrease in the MCF-7/Dox, (2) the extra energy produced by the PGP+ mutants comes from anaerobic glycolysis, and (3) when aerobic metabolism is blocked, the PGP+ mutants are capable of obtaining from two-to threefold more energy anaerobically than the parental cell line.
Computational models
The principle of AT is that the competition between chemosensitive and chemoresistant tumor cells would reduce the growth rate of both populations.
Conventional high-dose therapy sharply decreases the sensitive tumor sub-population, which allows the re-growth of drug resistant clones. To avoid this negative effect, AT proposes to treat patients with the minimum drug concentration required to maintain tumor burden below a disease-inducing level. 
Our simulations using AT showed that the drug resistant population could be maintained stable, if at least one of two conditions were satisfied: (1) Our simulations showed that, compared to traditional high-dose density therapy, patients with initial prevalence of 10% PGP+ cells (figure 4) have a 2 to 3-fold increase in progression-free survival using AT, and a 4-fold increase when AT was enhanced using verapamil and 2-deoxyglucose.
In patients with a smaller chemoresistant sub-population, progression-free survival (compared to MTD) is improved by a factor of 4 with AT, and by a factor of 10 with the AT + verapamil + 2-deoxyglucose combination (figure 5). 
Discussion
We previously proposed that the growth of sub-populations of resistant clones in a heterogeneous tumor could be suppressed, if a competing chemo-sensitive population were spared. This approach, termed Adaptive Therapy, explicitly limits application of chemotherapy to maintain a stable population of chemo-sensitive cells that, through their fitness advantage in the absence of therapy, suppress proliferation of resistant phenotypes.
Although this initially appears to be a radical departure from conventional high dose density therapy, the concept of AT, which uses a lower dose and more tolerable chemotherapy, is in agreement with the clinical goals for the treatment of metastatic breast cancer. That is, chronic long-term treatment with intermittent breaks and/or frequent dose reductions occurs regularly due to toxicity. Additionally, quality of life is an important aspect of therapy because the treatment is ongoing and not curable.
Therefore, treatment at the MTD, especially in the long term, is difficult to maintain. Thus, the AT strategy seeks to employ conventional practice but use evolutionary principles to obtain optimal long-term tumor control.
Traditional attempts to circumvent cancer cell resistance to chemotherapy have focused on using PGP substrates to compete for membrane efflux pumps, and increase intracellular accumulation of chemotherapy. In vitro studies have shown that verapamil and quinidine cause intracellular chemotherapy accumulation only when present in high concentrations (~10μM for both (7), (25) observed in clinical trials were 5.5μM for quinidine (11) , and 0.5μM for verapamil (10)).
Thus, it is not surprising that clinical results for combining chemotherapy and verapamil were disappointing. Furthermore, PGP is only one of several intra-and extra-cellular drug resistance mechanisms (26) .
Here we propose an extension of this strategy that exploits the many available PGP substrates. We hypothesize that non-chemotherapeutic PGP-substrate drugs might be used to increase the metabolic cost of MDR, reducing the fitness of the over-expressing PGP cells during chemotherapy intervals.
Since PGP over-expressing cells consume ATP to extrude drugs, we propose that the chronic administration of non-chemotherapeutic PGP substrates will exhaust resources in the chemoresistant population, reducing their ability to proliferate. Thus, our goal, rather than inhibiting chemotherapy efflux, is to increase futile PGP activity during chemotherapy intervals. Unlike previous MDR-modulating therapies, our approach does not require that PGP be the sole mechanism of drug resistance, but simply one of the mechanisms.
To test our hypothesis, we built a computational model of hypothetical patients with different initial prevalence of PGP mutant clones. We parameterized the model using in vitro studies of the breast cancer cell MCF-7 and a related chemoresistant line overexpressing PGP pumps (MCF-7/Dox). We find MCF-7/Dox consumes more energy than its parental cell line (MCF-7), as previously determined for other PGP mutant cell lines (14, 15, 18) , and that this higher energetic need is supplemented by anaerobic glycolysis. The percentage of PGP+ mutants in our simulations was estimated from three clinical trials with breast cancer patients, which have estimated PGP+ prevalence in untreated patients from undetectable (27) to below 10% (23), (28) . Moreover, these pumps were shown to be functional and to confer drug resistance ex vivo (28) . The presence of PGP+ cells was also detected in the surrounding desmoplastic stroma of breast cancer patients 
Computational simulations of hypothetical patients treated with standard maximum tolerated dose (MTD), Adaptive Therapy (AT), and AT combined with nonchemotherapeutic PGP substrates and 2-deoxyglucose, show dramatic differences in progression-free survival. Compared to traditional high-dose density therapy, patients with initial prevalence of 10% PGP+ cells will have a 2 to 3-fold increase progressionfree survival using AT, and a 4-fold increase when AT was combined with verapamil and 2-deoxyglucose. When 5% or fewer drug resistant cells are initially present, progressionfree survival is improved by a factor of 4 with AT, and by a factor of 10 with the AT/ verapamil/2-deoxyglucose combination.
The chronic combined doses of 2-DG/verapamil proposed in this manuscript were 5mM/0.1uM, respectively, which would be sufficient to mimic in blood the results from the low glucose culture media. Clinical trials with glioblastoma patients have reached weekly boluses as high as 1.25mM for up to 7 weeks (33), while chronic administration of 2-DG at 0.18mM was achieved in a clinical trial with patients with solid tumors (34).
Similar to chemotherapeutic agents, the chronic administration of glycolytic inhibitors may cause toxicity to healthy tissues. In the case of 2-DG the most affected would be the brain, retinae, and other organs with known high glucose consumption (35) . Dietary interventions, such as reduction in carbohydrate uptake, as well as increases in the doses of verapamil, can be envisioned as alternative ways of reaching the same goal of cost of resistance of PGP+ mutants.
For the sake of simplicity, the computational model assumed that the conversion rate of chemosensitive cells into PGP+ chemoresistant cells was negligible. While it is difficult to determine the spontaneous and drug-induced mutation rate in patients, in vitro 
experiments have suggested this conversion rate is about 1.8 x 10 -6 /generation (36) .
When this spontaneous rate of conversion from a sensitive to a resistant state is added to the original simulations, the progression free survival (PFS) and observed survival (OS) from the example in figure 5 are reduced from 500 and 590 days, respectively, to 475 and 560 days, respectively.
As a next step, the approach here proposed will be tested in mouse models (Nu/Nu) using the same cell lines (MCF-7 and MCF-7/Dox) with doxorubicin as chemotherapeutic agent in combination with verapamil and 2-deoxyglucose A mixed population of tumor cells will be injected in the mammary fat pad and the tumor volume will be monitored by caliper measurements and ultrasound.
In summary, we investigate an alternative cancer treatment strategy that is explicitly designed to maintain a residual population of therapy-sensitive cancer cells so that they can use their fitness advantage to suppress proliferation of resistant phenotypes.
Essentially, we accept the continued presence of cells that we can potentially kill so that they can reduce the growth of populations that we cannot, and could ultimately lead to patient death. We have previously demonstrated, using computation models and in vivo experiments, that this approach prolongs survival, while using lower drug doses, so that quality of life is high. Here, we hypothesize that the addition of non-chemotherapy PGP substrates, between treatments, will further burden the chemoresistant clones and increase their relative fitness disadvantage, when compared to chemosensitive cells. We demonstrate, using computational models parameterized by in vitro studies with clinically available drugs, that this approach can potentially increase the time to tumor recurrence in breast cancer patients by 4 to 10-fold. figure 1 and supplementary table 1 . The IC50 for the chemosensitive sub-population was arbitrarily set to 1, while for the PGP+ mutant, it was considered to be 100-fold higher. The standard therapeutic dose was also set as one arbitrary unit, and the initial dose of the adaptive therapy algorithm was set as half this value. 
